The Department-Related Parliamentary Standing Committee on Health and Family Welfare has urged the Ministry of Health to ensure the timely implementation of the BPaLM regimen for multi-drug resistant tuberculosis (MDR-TB) across India. The panel emphasized the need for a strategic approach to research, fostering innovation in diagnostics and drug regimens.
Faster and More Effective Treatment Approved
The Indian government recently approved the BPaLM regimen, which includes bedaquiline, pretomanid, linezolid, and moxifloxacin. Research shows that this new treatment is safer, more effective, and significantly faster, reducing the treatment duration for MDR-TB from 20 months to just six months. Recognizing its critical role in achieving WHO’s TB elimination goals, the panel, led by MP Prof. Ram Gopal Yadav, called for nationwide implementation in collaboration with states and union territories.
Strengthening Research and Innovation
The panel highlighted the importance of research and innovation in combating TB. It recommended a structured approach to research by organizations like the Indian Council of Medical Research (ICMR) and the India TB Research Consortium. This includes meticulous planning, increased funding, and greater autonomy to accelerate discoveries. The committee also stressed the need for clear timelines and accountability in research efforts. Additionally, it urged universities and medical colleges to actively participate in TB research.
Addressing Delays in Diagnostics and Drug Procurement
To prevent delays in adopting new diagnostic methods and drug regimens, the panel recommended prompt reviews and efficient procurement processes. It pointed out administrative delays in acquiring essential reagents and kits, which have led to shortages. The committee urged the government to maintain a steady supply of diagnostic tools like Cartridge-Based Nucleic Acid Amplification Test (CBNAAT) and Truenat cartridges, which are essential for early TB diagnosis.
Enhancing Supply Chain and Local Manufacturing
The Ministry informed the panel about the Ni-kshay Aushadhi platform, which monitors drug and diagnostic supplies. However, the committee called for streamlining procurement procedures to ensure a consistent supply. It also recommended promoting local manufacturing by offering special incentives, which would boost domestic production and strengthen the supply chain for essential healthcare products.
Government’s Commitment to TB Elimination
The Ministry assured the panel that it is procuring new drugs and drug regimens. These have been recommended by the ICMR for rapid nationwide scaling. It also stated that new diagnostic methods are incorporated into the National TB Elimination Programme (NTEP) guidelines based on feasibility and scalability.
To support these efforts, the government has set up a task force of medical colleges to assist in implementation and operational research.
Additionally, the ICMR has formed an expert committee to identify innovations and conduct feasibility studies. The India TB Research Consortium continues to develop new TB drugs, diagnostics, and vaccines. It is also working on effective implementation strategies.
The panel aims to strengthen India’s fight against tuberculosis by addressing challenges in drug rollout, diagnostics, and research. It also seeks to accelerate progress toward the disease’s elimination.